Drug Profile
BT 1718
Alternative Names: BT-1718Latest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator Bicycle Therapeutics
- Class Antineoplastics; Bicyclic peptide drug conjugates; Drug conjugates
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 20 Nov 2023 Cancer Research UK in collaboration with Bicycle Therapeutics completes a phase I/II trial in Solid tumours (In children, In adults, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (NCT03486730) (EudraCT2016-004633-24)
- 07 Apr 2023 Bicycle Therapeutics has patent protection for composition of matter, methods of use of BT 1718 for Cancer prior December 2022
- 06 Jan 2023 Phase II development in Solid tumours (In children, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) is still ongoing in United Kingdom (IV) (NCT03486730)